GLOW

Three repair peptides in one vial, each working a different layer of healing, with the emphasis on skin.

Evidence: DCommunity use what's this?
Grade D for the combination. Each component carries its own grade (GHK-Cu B, BPC-157 E, TB-500 E).
Also known as: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg (70 mg vial)
Class: Community repair-and-skin blend, 5:1:1 GHK-Cu-dominant. No trials of the blend itself.

The 30-second version

WhatGHK-Cu (matrix), BPC-157 (local repair, gut) and TB-500 (cell migration) in one injection.

Why people use itSkin texture and firmness first, then soft-tissue and post-surgical recovery.

The honest catchThe blend has never been trialled, and its TB-500 dose is light for a serious injury.

What it is

GLOW combines three of this guide’s repair peptides, usually pre-blended at five parts GHK-Cu to one part each of BPC-157 and TB-500. That ratio makes it GHK-Cu-dominant, so it leans toward skin and tissue quality more than heavy injury repair. Full pharmacology is in each chapter: BPC-157 (08), TB-500 (09), GHK-Cu (17). KLOW (20) adds KPV to this base.

Why the three combine

BPC-157: local protector. New vessels at the injury, calmer inflammation, gut support.

TB-500: systemic mobiliser. Moves repair cells body-wide through actin.

GHK-Cu: matrix rebuilder. Collagen, elastin and remodelling, with the best human data of the three.

Together: vessel growth, cell migration and matrix rebuilding at the same time.

Order of effects: gut and inflammation around week 2, skin around weeks 3–4, deeper repair over the cycle.

What the evidence supports

There are no trials of GLOW itself. The skin claims rest mainly on GHK-Cu’s placebo-controlled topical data. The recovery claims rest on BPC-157 and TB-500 animal work. The specific combination is community practice.

Evidence at a glance

Use	Grade	Best evidence	Main gap	Read
Skin and anti-ageing	DCommunity use	Driven by GHK-Cu (topical human data)	Blend untested	Best-supported use
Soft-tissue recovery	DCommunity use	BPC-157 + TB-500 animal data	No human trials	Plausible
Post-surgical healing, scarring	DCommunity use	Community reports	No trial	Plausible

Dosing: what has been reported

Not a recommendation. These figures describe what was studied or what circulates in practice, kept separate so you can see how solid each one is. Speak with a qualified clinician before acting on any of it.

Setting	Figure	Route	Grade
Pre-blend 5:1:1	900–1,800 mcg total blend per dose; start low	Subcutaneous	D
Frequency	Daily for skin; 3–5× weekly for repair; 4–8 weeks on, similar time off	—	D
Separate vials	BPC-157 200–500 mcg/day; TB-500 2–2.5 mg/week; GHK-Cu per its chapter	Subcutaneous	D

A common mix is 70 mg in 3 mL of bacteriostatic water. Daily dosing of the pre-blend delivers about 330 mcg of TB-500 per dose, which matches TB-500’s maintenance range. Use separate vials to push one component, for example more TB-500 for a real injury.

Preparing & storing

Reconstitute with bacteriostatic water, refrigerate, protect from light and don’t shake. The blue tint comes from the copper in GHK-Cu and is normal.

Reported side effects

Injection-site reactions (most common)
Brief tiredness after injection (TB-500)
Copper ceiling: GHK-Cu’s copper sets the practical upper dose

Who should avoid it

Active or suspected cancer: all three promote vessel growth or cell proliferation
Pregnancy and breastfeeding
Wilson’s disease or other copper disorders
Tested athletes: contains BPC-157 and TB-500, both WADA prohibited

Regulatory status checked Oct 2026

Body	Status	Detail
BPC-157	Not approved	WADA prohibited (S0).
TB-500	Not approved	WADA prohibited (S2).
GHK-Cu	Cosmetic ingredient	Not named by WADA.
GLOW blend	Not approved	Banned for tested athletes as a whole.

The NexGen read

A rational blend, strongest on skin

GLOW pairs three repair mechanisms that make sense together. Its best evidence comes from the GHK-Cu skin work. Cycle it, respect the copper ceiling and keep it away from any cancer history.

References

See component chapters: BPC-157 (08), TB-500 (09), GHK-Cu (17). No trials of the combination exist.